News | August 11, 2021
Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
Formulation business grew by 15 per cent in the quarter
Formulation business grew by 15 per cent in the quarter
The company has already embarked upon significant expansion in Turkey
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
The backing comes as influenza remains a persistent public health burden
The move comes as demand rises for wider access to glaucoma screening and more flexible clinical workflows
Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
The company said the safety profile remained consistent with earlier studies and was considered manageable
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Country’s deep scientific talent pool and its growing role as a clinical trial destination makes it central to how Parexel serves sponsors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
